Upcoming Clinical Milestones Will Drive Rare Disease Pipeline Expansion Into 2026

Key Takeaways

• Broader patient identification, international expansion, and supportive reimbursement environments are driving sustained revenue growth and improving margins for Mirum's portfolio.
  
• Advancing late-stage pipeline programs and leveraging precision medicine support future product expansion, revenue diversification, and long-term earnings acceleration.
  
• Heavy dependence on one therapy, regulatory and reimbursement risks, and competition from innovative treatments threaten revenue stability and long-term competitiveness.

Catalysts

A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

• The expanding addressable patient population for Mirum's therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth.
  
• Enhanced international market penetration-including successful new launches and reimbursement in key geographies like Japan and pending PFIC addition in Europe-positions Livmarli for durable global sales growth and operating scale, which should improve both revenue and gross margins.
  
• Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.
  
• Rising government incentives and global healthcare spending dedicated to rare and orphan diseases are expected to sustain favorable reimbursement environments and strong pricing power for Mirum's portfolio, driving robust net margins over the long term.
  
• Continued advances in precision medicine and genetics are improving rare disease diagnosis rates, accelerating patient identification for Mirum's products and supporting longer-term earnings growth through improved therapy adoption and earlier patient initiation.

Mirum Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Mirum Pharmaceuticals's revenue will grow by 22.8% annually over the next 3 years.
• Analysts assume that profit margins will increase from -13.6% today to 12.9% in 3 years time.
• Analysts expect earnings to reach $102.1 million (and earnings per share of $1.43) by about September 2028, up from $-58.6 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $16.7 million.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 53.2x on those 2028 earnings, up from -64.0x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
• Analysts expect the number of shares outstanding to grow by 4.65% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Mirum Pharmaceuticals Future Earnings Per Share Growth

Risks

• Mirum's significant reliance on Livmarli as its primary growth driver exposes the company to heightened revenue concentration risks; if competitors bring new therapies for Alagille or PFIC to market, or if regulatory or reimbursement hurdles emerge, top-line revenue growth could be significantly constrained.
  
• Substantial ongoing investments in R&D and SG&A to expand the pipeline and commercial reach, especially in international markets with complex and variable reimbursement processes, risk eroding net margins or causing cash flow volatility if new products underperform or launches are delayed.
  
• Accelerating advances in gene therapy and other novel modalities for rare diseases may outpace Mirum's small molecule approach, potentially making current products less competitive or clinically obsolete and leading to long-term revenue and earnings declines.
  
• Increasing scrutiny on global drug pricing, particularly for orphan drugs, and potential reductions in healthcare reimbursement or government budgets-especially in the wake of global economic uncertainty-could directly reduce Mirum's pricing power and patient access, lowering both revenue and net margins.
  
• Expansion into new markets and indications, especially with products like the upcoming EXPAND and VISTAS studies, is subject to regulatory risks and uncertainty regarding clinical outcomes in more heterogeneous or poorly characterized patient populations, increasing the likelihood of pipeline setbacks and missed revenue projections.

Valuation

• The analysts have a consensus price target of $78.273 for Mirum Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $89.0, and the most bearish reporting a price target of just $53.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $794.3 million, earnings will come to $102.1 million, and it would be trading on a PE ratio of 53.2x, assuming you use a discount rate of 6.8%.
• Given the current share price of $74.61, the analyst price target of $78.27 is 4.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.